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Novel fluconazole derivatives with promising antifungal activity
Nishad Thamban Chandrikaa,†, Sanjib K. Shresthaa,†, Huy X. Ngoa, Kaitlind C. Howarda, 
and Sylvie Garneau-Tsodikovaa,*
aUniversity of Kentucky, Department of Pharmaceutical Sciences, Lexington, KY, 40536-0596, 
USA
Abstract
The fungistatic nature and toxicity concern associated with the azole drugs currently on the market 
have resulted in an increased demand for new azole antifungal agents for which these problematic 
characteristics do not exist. The extensive use of azoles has resulted in fungal strains capable of 
resisting the action of these drugs. Herein, we report the synthesis and antifungal activities of 
novel fluconazole (FLC) analogues with alkyl-, aryl-, cycloalkyl-, and dialkyl-amino substituents. 
We evaluated their antifungal activity by MIC determination and time-kill assay as well as their 
safety profile by hemolytic activity against murine erythrocytes as well as cytotoxicity against 
mammalian cells. The best compounds from our study exhibited broad-spectrum activity against 
most of the fungal strains tested, with excellent MIC values against a number of clinical isolates. 
The most promising compounds were found to be less hemolytic than the least hemolytic FDA-
approved azole antifungal agent voriconazole (VOR). Finally, we demonstrated that the synthetic 
alkyl-amino FLC analogues displayed chain-dependent fungal membrane disruption as well as 
inhibition of ergosterol biosynthesis as possible mechanisms of action.
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1. Introduction
The rise in the number of infections caused by fungi poses a serious threat to human health 
and life.1 Fungal infections can be endogenous (e.g., Candida infections) or acquired from 
the environment (e.g., Cryptococcus and Aspergillus infections). Invasive fungal infections 
have become a major problem for patients with immunodeficiency syndrome (e.g., AIDS), 
organ transplant patients, and patients receiving chemotherapeutic agents for cancer 
treatment.2–4 Clinically, candidiasis, aspergillosis, and cryptococcosis are the major 
infections in immunocompromised patients.5, 6 Candida and Aspergillus species are 
responsible for the majority of documented fungal infections. Recent studies indicated an 
epidemiological shift towards infections caused by emerging non-albicans Candida and 
Aspergillus species resistant to the current antifungal drugs.7–9 Non-albicans Candida 
species such as C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei are more prominent 
now and they account for more incidence of invasive candidiasis such as candidemia than C. 
albicans.10–13 The relative presence of these fungal strains is region dependent. For example, 
C. glabrata is the second most common species after C. albicans in North America.14 Fungal 
strains such as C. parapsilosis and C. tropicalis are relatively more common in Europe, 
Australia, Latin America, and Asia.15–17 As resistance to the currently available antifungal 
agents is emerging in many of these non-albicans Candida, there is a need for developing 
novel antifungals.18
Most of the current drugs on the market are either highly toxic (e.g., amphotericin B (AmB)) 
or becoming ineffective due to appearance of resistant fungal strains (e.g., azoles such as 
fluconazole (FLC) and voriconazole (VOR)) (Fig. 1).19 Azoles are the most frequent class of 
antifungals used to treat fungal infections as they are inexpensive and are available for oral 
administration.20 However, there is an extensive documentation of intrinsic and developed 
resistance to azole drugs among C. albicans and non-albicans Candida species. As the 
frequency of occurrence of infections caused by non-albicans Candida species is increasing 
in clinical settings, there is currently a need to improve on the existing azole scaffolds to 
develop novel antifungals. Various studies were reported by our and other groups, which 
illustrated the role of alkylation on different drug scaffolds resulting in promising antifungal 
activity.21–27 There are examples of 2,4-difuoro-2-(1H-1,2,4-triazo-1-yl)acetophenone 
analogues with linear C5–C8 alkyl chains25 and of an n-alkylated ebsulfur derivative with a 
linear C5 alkyl chain, which displayed strong antifungal activity.24 Similarly, examples of 
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aminoglycosides (e.g., kanamycin B (KANB) and tobramycin (TOB)) with linear alkyl 
chains with 12 and 14 carbons (C12 and C14) displaying antifungal activity were also 
reported.21, 22
Based on the information provided above and the promise shown by these small molecules, 
herein, we decided to generate novel FLC derivatives in which the triazole ring on the 
carbon alpha to the dihalophenyl ring of FLC was displaced by various linear alkyl-, aryl-, 
dialkyl-, and cycloalkyl-amino substituents. We report the synthesis of twelve novel FLC 
derivatives (Fig. 2) and their antifungal activity against a variety of C. albicans, non-albicans 
Candida, Aspergillus, and Cryptococcus strains as established by in vitro MIC determination 
as well as by time-kill studies. We explore the hemolytic activity as well as cytotoxicity of 
these compounds against murine erythrocytes and mammalian cell lines, respectively. 
Finally, we investigate the potential mechanism of action of selected compounds by probing 
their ability to disrupt fungal membrane.
2. Results and discussion
2.1. Design and synthesis of antifungal agents 5-16
We synthesized the alkyl-/aryl- and cycloalkyl-amino FLC derivatives 5-16 in two steps by 
using the commercially available fluorinated compound 2,4-difuoro-2-(1H-1,2,4-triazo-1-
yl)acetophenone as a starting material (Fig. 2B). We first converted the carbonyl group of 
2,4-difuoro-2-(1H-1,2,4-triazo-1-yl)acetophenone to an epoxide by using 
trimethylsulfoxonium iodide in the presence of a strong base and a surfactant to yield the 
oxirane intermediate 4, which we then reacted with various amines (all commercially 
available, with the exception of amine 3 used in the synthesis of derivative 12) under mild 
basic conditions to afford derivatives 5-16. The amine 3 used for the synthesis of derivative 
12 was prepared in three steps (Fig. 2A). The amino group of 6-aminohexanol was protected 
with Boc to yield compound 1, which was then subjected to nucleophilic substitution 
reaction with 1-iodopentane. The deprotection of the Boc group of intermediate 2 yielded 
the desired amine 3.
2.2. Antifungal activity and structure-activity-relationship (SAR) analysis
We first evaluated the antifungal activity of the newly prepared FLC derivatives 5-16 against 
a panel of seven C. albicans (ATCC 10231 (A), ATCC 64124(R) (B), ATCC MYA-2876(S) 
(C), ATCC 90819(R) (D), ATCC MYA-2310(S) (E), ATCC MYA-1237(R) (F), and ATCC 
MYA-1003(R) (G)), three non-albicans Candida (C. glabrata ATCC 2001 (H), C. krusei 
ATCC 6258 (I), and C. parapsilosis ATCC 22019 (J)), and three Aspergillus (A. flavus 
ATCC MYA-3631 (K), A. nidulans ATCC 38163 (L), and A. terreus ATCC MYA-3633 
(M)) strains using a concentration range of 0.03-31.3 μg/mL (Tables 1 and S1). We used the 
commercially available antifungal agents such as AmB, caspofungin (CAS), FLC, and VOR 
as positive controls for comparison. For derivatives 5-16 as well as the reference drugs AmB 
and CAS, we reported MIC-0 values, which correspond to no visible growth. We reported 
MIC-2 values (i.e., 50% growth inhibition) for FLC and VOR against all fungal strains 
tested with the exception of strain A by VOR. We defined antifungal activity as excellent 
(0.03-1.95 μg/mL), good (3.9 μg/mL), moderate (7.8-15.6 μg/mL), or poor (≥31.3 μg/mL) 
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based on MIC values. In this manuscript, we performed all activity comparisons by using the 
MIC values reported in μg/mL (Note: the corresponding MIC values are also provided in μM 
into parentheses in Tables 1, 2, S1, and S2).
By a survey of the data reported in Table 1, the following observations could rapidly be 
made. The introduction of a side-chain comprising (i) a terminal hydroxyl group as in 
compound 11, (ii) a dialkyl-amino moiety as in derivatives 13 and 14, (iii) a cycloalkyl-
amino group as in compound 15, and (iv) an aryl-amino functionality as in compound 16, 
resulted in all cases in molecules that were generally poor antifungals. A few exceptions 
were noted: compounds 14 and 15 displayed excellent (0.975 μg/mL) and good (3.9 μg/mL) 
activity against the C. parapsilosis strain J. In contrary, we found that mono-alkylation 
resulted in much better antifungals. For derivatives 5-10, we generally observed better 
activity against non-albicans Candida and Aspergillus strains than against C. albicans. More 
specifically, when exploring the data for strains H–M, we found that compounds 7 and 8 
displayed excellent (0.03-1.95 μg/mL) activity against the non-albicans Candida strains H, I, 
and J, as well as against the Aspergillus strain L. Additionally, both compounds 7 and 8 
exhibited moderate (7.8 μg/mL) and good (3.9 μg/mL) activity against the Aspergillus 
strains K and M, respectively. Compounds 5, 6, 9, and 10, displayed excellent activity 
(0.06-1.95 μg/mL) against strains J, (I, J and L), (H and J), and (H and J), respectively. 
Compounds 5, 6, and 9 displayed moderate activity (7.8-15.6 μg/mL) against strains (H and 
I), (H and M), and M, respectively. In addition, derivatives 9 and 10 showed good (3.9 
μg/mL) activity against strains I and L. When assessing the data for the C. albicans strains 
A–G, we found that compounds 6-9 exhibited excellent activity (0.48-1.95 μg/mL) against 
strain A. We also observed that derivatives 7 and 8 generally displayed good to moderate 
(3.9-15.6 μg/mL) activity against strains B–G, with the exception of compound 8 displaying 
excellent (1.95 μg/mL) activity against strain D. In addition, compounds 7 and 8 displayed 
excellent to good antifungal activity against most strains tested and derivative 9 displayed 
strong activity against non-albicans Candida and Aspergillus strains. These data indicated 
that the optimal chain lengths for maximal antifungal activity were C10 and C12, and the 
general trend for activity versus chain length was C10 > C12 > C8 > C14 > C16 = C6. Finally, 
we observed that replacing one of the carbon atom in the side-chain by an oxygen as in 
compound 12 was detrimental as its activity against all strains was generally lower (higher 
MIC values) than that of its counterpart 8.
Having established that derivatives 5-16 displayed excellent antifungal activity against non-
albicans Candida strains, we further evaluated these compounds against three clinical strains 
of C. glabrata (CG1, CG2, and CG3) and C. parapsilosis (CP1, CP2, and CP3), as well as 
three Cryptococcus neoformans (CN1, CN2, and CN3) clinical isolates (Table 2). The 
trends observed in Table 2 correlated perfectly to those described for the data presented in 
Table 1. Compounds 11 and 13 were inactive against all nine clinical isolates tested, whereas 
compounds 14-16 exhibited excellent to good (0.975-3.9 μg/mL) activity against C. 
parapsilosis CP1, CP2, and CP3. For derivatives 5-10, we generally observed excellent 
activity against most C. glabrata, C. parapsilosis, and C. neoformans clinical isolates. More 
precisely, we found that compound 8 displayed excellent (0.06-1.95 μg/mL) activity against 
all clinical isolates tested. Compounds 7, 9, and 10 displayed excellent (0.03-1.95 μg/mL) 
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activity against all isolates, with the exception of C. glabrata CG3. In addition, compound 6 
displayed excellent (0.12-1.95 μg/mL) activity against CG2, CP1, CP2, CP3, and CN1, 
whereas compound 5 was found to display excellent (0.975 μg/mL) activity against C. 
parapsilosis CP1, CP2, and CP3 isolates. Overall, compounds 6-10 displayed better activity 
against the clinical isolates presented in Table 2 than they did against the commercially 
available strains for which the data are presented in Table 1. In general, we found that the 
three most active compounds synthesized (based on the data from Tables 1 and 2), 7–9, 
displayed better activity than FLC and similar or better activity than AmB against most of 
the fungal strains tested, as well as better activity than CAS against the three Aspergillus 
strains tested. When examining the data obtained with clinical isolates of C. glabrata, C. 
parapsilosis, and C. neoformans (Table 2), we observed that compounds 7-9 displayed 
similar or better activity than both CAS and FLC. When comparing compounds 7-9 to VOR, 
we found them to display stronger activity against some of the clinical strains tested.
The antifungals currently on the market are known to bind to proteins and be less efficient in 
intracellular matrices. For this reason, we tested the three best compounds, 7-9, against three 
representative strains, the C. albicans A, the non-albicans Candida (C. parapsilosis) J, and 
the Aspergillus L, in presence and absence of fetal bovine serum (FBS) (Table 3). We found 
that the alkyl-amino azole analogue 7 retained its full antifungal activity (only 1 double 
dilution difference in some cases) against all three strains tested in the presence of FBS. 
Compound 8 retained its full activity against strain J and experienced a 2- and 4-fold 
decrease in activity in the presence of FBS against strains A and L, respectively. Compound 
9 displayed a 2- to 8-fold decrease in activity against the strains tested. Even though there 
was a small loss in activity in some instances, analogues 7-9 still remained good antifungal 
with the exception of compound 9 against strain L.
2.3. Time-kill studies
The information regarding the rate and extend of fungicidal activity can be gathered by time-
kill assays. To determine the fungistatic or fungicidal nature of the compounds generated, 
we performed time-kill assays over a 24-h period with one of the best FLC derivatives, 
compound 7, and one of the good ones, compound 6. These compounds and VOR (positive 
control) were tested against fungal strains C. albicans ATCC 10231 (A) and C. parapsilosis 
ATCC 22019 (J) (Fig. 3). At 4× their respective MIC values, when tested against strain A, 
compounds 6 and 7 were found to be fungistatic and to be better than the control drug VOR. 
When tested against strain J, both compounds also displayed fungistatic activity at up to 4× 
their MIC values. However, against strain J, compound 6 displayed lower reduction in 
fungal growth than VOR, but compound 7 displayed activity equal to VOR. Overall, the 
compounds 6 and 7 performed better in time-kill studies than the control drug VOR.
2.4. Hemolysis assay
The promising antifungal activity shown by the synthetic analogues demanded further safety 
analysis for these compounds. We tested compounds 6-10 for their hemolytic activity against 
murine red blood cells (mRBCs) (Fig. 4 and Table S3). Compounds 6 (C8) and 7 (C10) 
displayed <10% and <40% hemolysis at concentrations of 31.3 μg/mL (1- to 512-fold of its 
overall MIC values) and 15.6 μg/mL (1- to 512-fold of its overall MIC values), respectively. 
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Similarly, compound 8 (C12) induced only 21% lysis at 7.8 μg/mL (1- to 218-fold of its 
overall MIC values). In addition, compounds 9 (C14) and 10 (C16) displayed <50% and 
<10% hemolysis at concentrations of 31.3 μg/mL (1- to 256-fold of its overall MIC values) 
and 62.5 μg/mL (2- to 128-fold of its overall MIC values), respectively. By comparing the 
hemolysis of compounds 6-10 with their corresponding MIC values against the non-albicans 
Candida, A. nidulans, and C. neoformans strains tested, we concluded that all of these 
compounds displayed minimal hemolytic activity. Overall, compounds 6 and 10 displayed 
the lowest hemolytic activity. Importantly, some of the newly synthesized compounds 
displayed less hemolytic effect than the FDA-approved control drug VOR.
2.5. In vitro cytotoxicity assay
Another crucial parameter to consider when developing antifungal drugs is their selectivity 
for fungal over mammalian cells. We tested our active compounds 6-10 against three 
different cell lines, HEK-293, BEAS-2B, and A549, along with the FDA-approved 
antifungal agent VOR as a positive control (Fig. 5). Against HEK-293, compounds 6, 7, and 
10 exhibited no toxicity up to 31 μg/mL (1- to 512-fold of its overall MIC values), 7.8 
μg/mL (1- to 256-fold of its overall MIC values), and 7.8 μg/mL (1- to 16-fold of its overall 
MIC values), respectively. However, compounds 8 and 9 exhibited some toxicity (>50% cell 
survival) at a concentration of 3.9 μg/mL (1- to 64-fold of its overall MIC values) against 
HEK-293. Interestingly, compounds 8-10 were non-toxic to both BEAS-2B and A549 at up 
to 7.8 μg/mL (1- to 128-fold of its overall MIC values). In the case of compound 6, no 
toxicity was observed against BEAS-2B (at 31 μg/mL) (1- to 512-fold of its overall MIC 
values) and A549 (at 15.5 μg/mL) (1- to 256-fold of its overall MIC values). With compound 
10 we basically observed no toxicity against BEAS-2B and A549 at 7.8 μg/mL (1- to 16-fold 
of its overall MIC values). A general trend of greater toxicity with respect to longer chain 
substitution was observed against the three cell lines. Compounds 6 and 7 exhibited better 
overall safety profiles than compounds 8-10. When considering the very low MIC values for 
these analogues against clinical isolates, these cytotoxicity data provide us with a reasonable 
therapeutic window.
2.6. Membrane permeabilization assay
Some amphiphilic molecules have been shown to cause membrane disruption and fungal cell 
death. Therefore, we decided to study the potential effect of compounds 8 and 9 with C12 
and C14 linear alkyl chains to determine the impact of chain length on membrane disruption 
(Fig. 6). The control drug VOR and the KANB (C14) derivative with a 14-carbon linear alkyl 
chain, were used as negative and positive controls, respectively. The propidium iodide (PI) 
dye was used as a probe as it can only enter cells with compromised membrane and bind to 
nucleic acid to emit fluorescence, which can be observed under a fluorescence microscope. 
At 4× MIC, the positive control KANB (C14) significantly increased PI dye uptake by C. 
albicans ATCC 10231 (strain A), whereas the negative control VOR (at 4× MIC) did not 
allow for PI uptake by fungal cells. Compound 8 with a C12 linear alkyl chain (at 4× MIC) 
induced cellular uptake of PI dye into C. albicans ATCC 10231 (strain A), whereas 
compound 9 (with a C14 linear alkyl chain) did not cause cell membrane disruption. 
Interestingly, the chain length played a crucial role on membrane disruption of C. albicans 
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ATCC 10231 (strain A), surprisingly with C12 being more membrane disrupting than C14. In 
order to completely understand the effect of chain length on membrane disruption, we 
additionally performed membrane permeabilization with compounds 5, 6, and 7 (C6–C10 
linear alkyl chains) at 4× MIC. None of these compounds induced cellular uptake of the PI 
drug. From this study, we can conclude that one of the possible mechanisms of action for 
compound 8 is membrane disruption. Interestingly, any other linear chains beside the C12 
displayed no membrane disruption.
2.7. Sterol profile by GC-MS
Since out of our compounds displaying antifungal activity only compound 8 caused 
membrane disruption of C. albicans ATCC 10231 (strain A) in the membrane 
permeabilization assay (section 2.6), we decided to explore by using gas chromatography-
mass spectrometry (GC-MS) the effect of compounds 8 and 9 on sterol composition during 
ergosterol biosynthesis (the mechanism of action of other conventional azoles) (Fig. 7). We 
evaluated the effect of the compounds 8 and 9 on sterol composition in C. albicans ATCC 
10231 (strain A) at sub-MIC levels of 0.48 μg/mL (Fig. 7D) and 0.975 μg/mL (Fig. 7E), 
respectively. We also used VOR at 0.12 μg/mL and no drug control for comparison (Fig. 7B 
and 7A, respectively). In the absence of drug, strain A accumulated 100% ergosterol (2), 
suggesting that the sterol biosynthesis was fully functional in this fungal strain. When 
treating strain A with VOR, we detected a lower amount of ergosterol (2, 50.80%), and an 
increased amount of lanosterol (1, 15.21%) and eburicol (3, 1.73%). However, when strain A 
was treated with compound 8, we observed a relatively low amount of ergosterol (2, 
36.62%) compared to VOR, but observed lower amounts of lanosterol (1, 10.03%), eburicol 
(3, 0.57%), and the fungistatic metabolite 14α-methyl ergosta-8,24(28)-diene-3β,6α-diol (4, 
4.69%) with respect to VOR. Interestingly, when strain A was treated with compound 9, we 
observed similar reduction in the amount of ergosterol (2, 36.43%) along with a related 
increase in lanosterol (1, 15.56%), eburicol (3, 1.16%) and the fungistatic metabolite 14α-
methyl ergosta-8,24(28)-diene-3β,6α-diol (4, 15.56%). From these experiments, we can 
conclude that our compounds inhibit ergosterol biosynthesis similarly to the azole drug 
control VOR.
3. Conclusions
In summary, we have synthesized novel FLC derivatives in which the triazole ring on the 
carbon alpha to the dihalophenyl ring of FLC was displaced by various linear alkyl-, aryl-, 
dialkyl-, and cycloalkyl-amino substituents. We did not detect any antifungal activity with 
the aryl- and cycloalkyl-amino substituted FLC analogues. We observed that the antifungal 
activity of the alkyl-amino FLC derivatives depends on the length of the alkyl chains. 
Compounds 6-9 were identified as promising antifungal agents with low hemolytic activity 
and low cytotoxicity. These analogues displayed great activity against some of the C. 
albicans, non-albicans Candida, and Aspergillus strains, and, in addition they were 
particularly excellent against the clinical strains of C. glabrata, C. parapsilosis, as well as C. 
neoformans tested. These compounds also exhibited superior activity against the clinical 
strains when compared to the control drugs CAS, FLC, and VOR. The possible mechanism 
of action for these FLC analogues was identified as membrane disruption with compound 8 
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with a C12 alkyl chain being more membrane disrupting than compound 9 with a C14 alkyl 
chain. Additionally, they were found to inhibit ergosterol biosynthesis. In the future, outside 
of the scope of this work, it will be interesting to see how these promising molecules will 
fair in the drug development process.
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Fig. 1. 
Structures of all antifungal agents used as controls in this study.
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Fig. 2. 
Synthetic schemes for the preparation of A. amine derivative 3, and B. novel azole analogues 
5-16.
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Fig. 3. 
Representative time-kill curves for compounds 6 and 7 against C. albicans ATCC 10231 
(strain A; panels A and C, respectively) and C. parapsilosis ATCC 22019 (strain J; panels B 
and D, respectively). Fungal strains were treated with no drug (black circles), 1× MIC (white 
circles), 2× MIC (inverted black triangles), or 4× MIC (white triangles) of compounds 6 or 
7, or with 4× MIC (black squares) of VOR. The experiments were performed in duplicate.
Chandrika et al. Page 13
Bioorg Med Chem. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 4. 
3D bar graph depicting the dose-dependent hemolytic activity of azole derivatives 6-10 and 
VOR against mRBCs, which were treated and incubated for 1 h at 37 °C with each 
compound tested at concentrations ranging from 0.48-62.5 μg/mL. Triton X-100® (1% v/v) 
was used as a positive control (100% hemolysis, not shown).
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Fig. 5. 
Representative cytotoxicity assays of compounds 6-10 against three mammalian cell lines: 
A. HEK-293, B. BEAS-2B, and C. A549. Cells were treated with various concentrations of 
compounds 6 (yellow), 7 (orange), 8 (turquoise), 9 (blue), 10 (pink), and VOR (purple). The 
positive control consisted of cells treated with Triton X-100® (TX, 20% v/v, pink). The 
negative control consisted of cells treated with DMSO (no drug, green). The experiments 
were performed in duplicate.
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Fig. 6. 
Effect of the controls VOR (negative) and KANB (C14) (positive) as well as compounds 5-9 
on the cell membrane integrity of C. albicans ATCC 10231 (strain A). For the three columns 
on the left from top to bottom: Propidium iodide (PI) dye uptake by yeast cells without drug, 
with VOR (0.975 μg/mL), KANB (C14) (31.3 μg/mL), and compound 8 (1×, 2×, and 4× 
MIC). For the three columns on the right from top to bottom: Propidium iodide (PI) dye 
uptake by yeast cells with compound 9 (1×, 2×, and 4× MIC), as well as compound 5, 6, and 
7 at 4× MIC. The experiments were performed in duplicate.
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Fig. 7. 
A. A simplified ergosterol biosynthetic pathway and products resulting from inhibition of 
ERG11. B–E. GC-MS chromatograms of the sterols extracted from untreated and 
antifungal-treated C. albicans ATCC 10231 (strain A). The fungal strain treated with DMSO 
(no drug control, panel B), VOR at 0.12 μg/mL (panel C), compound 8 at 0.48 μg/mL (panel 
D), and compound 9 at 0.975 μg/mL (panel E). The peaks in these chromatograms are for 
lanosterol (1), ergosterol (2), eburicol (3), 14α-methyl ergosta-8,24(28)-dien-3β,6α-diol (4). 
F. A table summarizing the percentage of each sterol from panels B–E.
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